Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
An important observation is that this patient
2023-02-08

An important observation is that this patient has been on ALK inhibitor for more than 4 years (51 months: 27 months on crizotinib+24 months on alectinib and on-going) and there was no evidence of disease progression in the central nervous system. The other potential driver mutation in this patient’s
-
The direction of glutamate transport by the cell membrane tr
2023-02-07

The direction of glutamate transport by the cell membrane transporter is reversible. As mentioned above, glutamate transport is an electrogenic process associated with a transmembrane ion gradient established by the Na+-K+ pump through hydrolysis of adenosine triphosphate. Under conditions of energy
-
AdK as an important upstream regulator of adenosine based ho
2023-02-07

AdK as an important upstream regulator of adenosine-based homeostasis represents a promising drug target since it leads to an increase in adenosine concentrations. Taking into account that the adenosine formation is only increased in affected tissues under stress with high adenosine levels, AdK inhi
-
(-)-Quinpirole hydrochloride The pathogenesis of d penicilla
2023-02-07

The pathogenesis of d-penicillamine-induced MG is not clear. The repertoire of anti-AChR (-)-Quinpirole hydrochloride in d-penicillamine-induced MG has been shown to be similar to that in idiopathic MG in terms of AChR antigenic regions, suggesting a common immune mechanism (Tzartos et al., 1988).
-
Among different classes of pesticide organophosphates
2023-02-07

Among different Nile Red of pesticide, organophosphates as well as pyrethroids are more frequently used because of their high insecticidal property, low mammalian toxicity, less persistence and rapid biodegradability in the environment. These compounds are used extensively in agriculture supposed to
-
sesamin receptor It is already established in the literature
2023-02-07

It is already established in the literature that products synthesized by 5-LO, such as lipoxin A4, can activate PPARγ in a setting of experimental stroke [43]. Interestingly, experiments using 5-LO knockout mice in an endotoxemia model to mimic septic conditions, demonstrated reduced multiple organ
-
The role of DHT in early teleost embryogenesis is
2023-02-07

The role of DHT in early teleost embryogenesis is not entirely clear or established, however additional studies that treat fish embryos to DHT or to specific srd5a inhibitors at critical stages of development (i.e. prior to sex differentiation) will shed light on the early functions of this androgen
-
The Kelch like ECH associated protein
2023-02-07

The Kelch-like ECH-associated protein 1 (Keap1)-Nrf2 signaling pathway functions as one of the key regulator of the cellular defense system against oxidative stress [26]. Nrf2 is a redox-sensitive transcription factor, that is sequestered in the cytoplam by binding to Keap1; however, under oxidative
-
Several studies have demonstrated that depletion of function
2023-02-07

Several studies have demonstrated that depletion of functional ATR increases the sensitivity of cancer cells to oncogene-induced replication stress thereby hindering tumour growth and inducing extensive cell death (Gilad et al., 2010, Murga et al., 2011, Schoppy et al., 2012). Importantly, Schoppy e
-
br Conflicts of interest br Financial support
2023-02-07

Conflicts of interest Financial support This work was supported by grants from the Fondazione Cariplo [Grant number 2011-0463] (Carini); and by Funds for Original Research of the Università del Piemonte Orientale (2016, Project: Carini-Boldorini). The sponsors had no involvement in study desig
-
A different mechanism has been suggested for the role of
2023-02-07

A different mechanism has been suggested for the role of TRX1 in ASK1 regulation based on disulfide bond-mediated ASK1 multimerization and its reduction through the thiol-reductase activity of TRX1 (Nadeau et al., 2007, Nadeau et al., 2009). In this model, oxidative stress induces intermolecular dis
-
To further evaluate the influence of antibiotics on allergy
2023-02-07

To further evaluate the influence of Mirin on allergy, Russel et al. initiated vancomycin treatment during pregnancy in mice and continued it for several weeks after birth. This resulted in exaggerated OVA-induced allergic inflammation, characterized by higher numbers of lung eosinophils, elevated c
-
br Role of AMPK in inflammation signaling
2023-02-07

Role of AMPK in inflammation signaling Pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), activate Ikβ kinase (IKKβ), which phosphorylates IκBα, triggering the degradation of proteasomal IκB. This liberates active nuclear factor kB (NF-kB) to translocate i
-
br Results The newly synthesized leucine ureido derivatives
2023-02-07

Results The newly synthesized leucine ureido derivatives were firstly evaluated for their enzymatic inhibition using porcine kidney APN (Microsomal, Biocol) with bestatin as the positive control (Table 1). One isoleucine ureido derivative 14 and phenylglycine ureido derivative 15 were also synthe
-
br Development of lorlatinib from crizotinib to a clinical
2023-02-07

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
16455 records 367/1097 page Previous Next First page 上5页 366367368369370 下5页 Last page